OUTPACE

Serial Number 99007123
641

Registration Progress

Application Filed
Jan 17, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Non-Final Action Mailed
Due: Oct 07, 2025 64 days

Trademark Image

OUTPACE

Basic Information

Serial Number
99007123
Filing Date
January 17, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
641
Status Date
Jul 7, 2025
Application
Pending
Classes
005

Rights Holder

Outpace Bio, Inc.

03
Address
700 Dexter Ave N, Ste 300
Seattle, WA 98109

Ownership History

Outpace Bio, Inc.

Original Applicant
03
Seattle, WA

Legal Representation

Attorney
Sydney R. Jensen

USPTO Deadlines

Next Deadline
64 days remaining
Non-Final Action Mailed
Due Date
October 07, 2025
Extension Available
Until January 07, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

6 events
Date Code Type Description Documents
Jul 7, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 7, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 7, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 27, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 17, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 17, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Medicines; drugs; pharmaceuticals; pharmaceutical preparations; therapeutics; therapeutic pharmaceuticals; therapeutic agents; cell therapies; biopharmaceuticals; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; drugs for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cells for medical or clinical purposes; viral or non-viral delivery vectors for medical or clinical purposes; proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; targeted cell therapies; cell therapy products; gene therapy products; therapeutic antigens and antibodies; engineered cells; bioengineered cells; cell engineering platforms; protein design platforms; computational protein design platforms; AI-powered protein design platforms; pharmaceutical preparations developed with a computational protein design platform; pharmaceutical preparations developed with AI-powered protein design platforms; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;

Classification

International Classes
005